Integ. Proteins (519606)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive book value of ₹1.14 per share means the company is not insolvent on reported numbers.
• Operates in edible oil, a defensive consumer staple category, if operations can be resumed.
• ROE of 9.58% is positive, though on a very small base.
• Market cap is just ₹7 Cr, so a small absolute profit could create large percentage growth if a genuine turnaround occurs.

Concerns

• Sales collapsed: latest quarter sales are ₹0 Cr, and sales growth is -100%.
• Profit growth is -128.57%, and latest quarter net profit is ₹-0 Cr, so earnings are negligible or negative.
• P/E of 291.79 and P/B of 19.24 leave no margin of safety against book value of ₹1.14.
• Piotroski F-Score of 3/9 and ROCE of 1.87% indicate weak financial health; promoter holding and debt/equity are not disclosed.

AI Analysis

Looking at Integ. Proteins, I am reminded of Graham's warning: you are neither right nor wrong because the crowd disagrees; you are right because your facts are right. Here the facts are alarming. The company had sales of ₹0 Cr in the latest quarter, sales growth of -100%, and profit growth of -128.57%. A business with no revenue is a business, but not one I can value with a P/E of 291.79; that multiple is meaningless, built on a sliver of earnings. Meanwhile, I am asked to pay ₹21.93 per share, 19.24 times book value, for a company whose book value is just ₹1.14. Benjamin Graham would demand a margin of safety; I see the opposite. ROCE is only 1.87%, and the Piotroski F-Score of 3/9 indicates very weak financial health. The return on equity of 9.58% looks respectable, but on this tiny base, with no sales, it does not compensate. The 52-week range shows the price has fallen from ₹136.95 to ₹21.93, an 84% decline. Markets are forward-looking, but a falling knife without earnings is still dangerous. There is no dividend yield to reward patient holding, and promoter holding is not disclosed, so I cannot judge alignment. FairStock says insufficient data; I agree. This is not an investment in a wonderful franchise at a fair price; it is a speculation on a potential turnaround. I do not speculate with capital I need to preserve. I will only reconsider when the company shows real sales, positive profits, and honest financials.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer